Thomas Briston is a scientist and project leader at Eisai. He received his Master of Pharmacy degree from the School of Pharmacy, University of London and completed his pre-registration training at the University Hospital of South Manchester. Dr. Briston obtained his PhD from UCL, studying the relationship between the oxygen-sensing pathway and E3-ubiquitin ligase VHL on mitochondrial form and function. His post-doctoral studies have continued to focus on mitochondrial biology, specifically that of the mitochondrial permeability transition pore and its potential as a drug target in Parkinson’s disease. Dr. Briston joined Eisai in 2015 and has since worked across multiple Parkinson’s disease drug discovery projects. He now leads a pre-clinical program in collaboration with UCL.